Antithrombotic Treatment of Stable Coronary Artery Disease

被引：4

作者：

Li, Yi-Heng ^{[1
]}

Hsieh, I-Chang ^{[2
]}

Ueng, Kwo-Chang ^{[3
]}

Wang, Yu-Chen ^{[4
,5
]}

Cheng, Shu-Meng ^{[6
]}

Wu, Cho-Kai ^{[7
,8
]}

Wu, Chiung-Jen ^{[9
,10
]}

Hsieh, Ming-Hsiung ^{[11
,12
]}

Jen, Hsu-Lung ^{[13
]}

Chang, Chi-Jen ^{[2
]}

Chen, Ying-Hwa ^{[14
,15
]}

机构：

[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Tainan, Taiwan

[2] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Taoyuan, Taiwan

[3] Chung Shan Med Univ Hosp, Taichung, Taiwan

[4] Asia Univ, Asia Univ Hosp, Taichung, Taiwan

[5] China Med Univ, Coll Med & Hosp, Taichung, Taiwan

[6] Triserv Gen Hosp, Natl Def Med Ctr, Taipei, Taiwan

[7] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[8] Natl Taiwan Univ Hosp, Taipei, Taiwan

[9] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan

[10] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[11] Taipei Med Univ, Taipei, Taiwan

[12] Taipei Wan Fang Hosp, Taipei, Taiwan

[13] Cheng Hsin Gen Hosp, Taipei, Taiwan

[14] Taipei Vet Gen Hosp, Taipei, Taiwan

[15] Natl Yang Ming Chiao Tung Univ, Taipei, Taiwan

来源：

ACTA CARDIOLOGICA SINICA | 2021年 / 37卷 / 06期

关键词：

Antithrombotics; Coronary artery disease; Dual antiplatelet therapy; Dual pathway inhibition; DUAL ANTIPLATELET THERAPY; MYOCARDIAL-INFARCTION; FOCUSED UPDATE; ESC GUIDELINES; MANAGEMENT; ASPIRIN; RISK; RIVAROXABAN; DETERMINANTS; VALIDATION;

D O I：

10.6515/ACS.202111_37(6).20210513A

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Coronary artery disease (CAD) is one of the leading causes of death in Taiwan. Despite the use of current guideline-recommended therapies for secondary prevention, the residual risk of recurrent cardiovascular events remains high in CAD, warranting the need for new treatment options. Antithrombotic drugs are one of the most important medical therapies for CAD. In this article, we review the unmet needs of the current antithrombotic agents and summarize the results of clinical trials with dual antiplatelet therapy in stable CAD. We also review data from a recent study demonstrating the benefits of a dual pathway inhibition strategy with antiplatelet and anticoagulant therapy, a new option for CAD treatment. Finally, we propose a treatment algorithm for choosing different antithrombotic regimens for CAD based on current scientific evidence and expert opinions.

引用

页码：574 / 579

页数：6

共 50 条

[31] Stable coronary artery disease
Scherger, JE
AMERICAN FAMILY PHYSICIAN, 1998, 57 (05) : 945 - 945
[32] Stable Coronary Artery Disease
Kallikazaros, Ioannis E.
HELLENIC JOURNAL OF CARDIOLOGY, 2014, 55 (02) : 175 - 177
[33] Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
Gremmel, Thomas
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25): : 2480 - 2481
[34] Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
Yasuda, Satoshi
Kaikita, Koichi
Akao, Masaharu
Ako, Junya
Matoba, Tetsuya
Nakamura, Masato
Miyauchi, Katsumi
Hagiwara, Nobuhisa
Kimura, Kazuo
Hirayama, Atsushi
Matsui, Kunihiko
Ogawa, Hisao
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (12): : 1103 - 1113
[35] The case for medical treatment in chronic stable coronary artery disease
Nash, DT
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (22) : 2587 - 2589
[36] Coronary artery bypass grafting is the treatment of choice for stable chronic coronary disease
Haverich, A.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (39) : 1938 - 1938
[37] How stable is stable coronary artery disease?
Konigstein, Maayan
Ben-Yehuda, Ori
CORONARY ARTERY DISEASE, 2017, 28 (08) : 632 - 633
[38] NOVEL ANTITHROMBOTIC APPROACHES TO CORONARY-ARTERY DISEASE
TOPOL, EJ
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (06): : B27 - B33
[39] Antithrombotic therapy in diabetic patients with coronary artery disease
Lemesle, G.
Bauters, A.
Bauters, C.
PANMINERVA MEDICA, 2015, 57 (02) : 87 - 99
[40] Antithrombotic Management of Elderly Patients With Coronary Artery Disease
Capranzano, Piera
Angiolillo, Dominick J.
JACC-CARDIOVASCULAR INTERVENTIONS, 2020, 14 (07) : 723 - 738

← 1 2 3 4 5 →